Cargando…
Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment
A 59-year-old woman with follicular thyroid carcinoma underwent total thyroidectomy followed by radioiodine treatment. Following treatment, the whole-body scan did not show any abnormal radioiodine uptake. However, during the follow-up, the serum thyroglobulin (Tg) value increased without detectable...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Endocrinologia e Metabologia
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832896/ https://www.ncbi.nlm.nih.gov/pubmed/35315988 http://dx.doi.org/10.20945/2359-3997000000451 |
_version_ | 1784868151840735232 |
---|---|
author | Ataei-Nakhaei, Saeideh Aryana, Kamran Mostafavi, Sayyed Mostafa Kosari, Hadis Mohammadzadeh Esmatinia, Mohammad Aghaee, Atena |
author_facet | Ataei-Nakhaei, Saeideh Aryana, Kamran Mostafavi, Sayyed Mostafa Kosari, Hadis Mohammadzadeh Esmatinia, Mohammad Aghaee, Atena |
author_sort | Ataei-Nakhaei, Saeideh |
collection | PubMed |
description | A 59-year-old woman with follicular thyroid carcinoma underwent total thyroidectomy followed by radioiodine treatment. Following treatment, the whole-body scan did not show any abnormal radioiodine uptake. However, during the follow-up, the serum thyroglobulin (Tg) value increased without detectable thyroglobulin-antibodies. We performed a Ga-68 DOTA-TATE PET/CT showing a sternal lesion and several lung nodules with high somatostatin receptor density. Also, on the next day, FDG PET/CT was performed, which confirmed the findings. Considering the high levels of somatostatin receptor expression in such metastases, we planned lu177 DOTA-TATE therapy. After two cycles of lu177 DOTA-TATE injection, serum thyroglobulin significantly dropped, and she claimed that her sternal pain and dyspnea were much better. This was the case of a patient suffering from iodine-refractory follicular thyroid carcinoma, with somatostatin-receptor expression, treated with 177Lu-DOTA-TATE, showing a significant response. |
format | Online Article Text |
id | pubmed-9832896 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Sociedade Brasileira de Endocrinologia e Metabologia |
record_format | MEDLINE/PubMed |
spelling | pubmed-98328962023-03-14 Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment Ataei-Nakhaei, Saeideh Aryana, Kamran Mostafavi, Sayyed Mostafa Kosari, Hadis Mohammadzadeh Esmatinia, Mohammad Aghaee, Atena Arch Endocrinol Metab Case Report A 59-year-old woman with follicular thyroid carcinoma underwent total thyroidectomy followed by radioiodine treatment. Following treatment, the whole-body scan did not show any abnormal radioiodine uptake. However, during the follow-up, the serum thyroglobulin (Tg) value increased without detectable thyroglobulin-antibodies. We performed a Ga-68 DOTA-TATE PET/CT showing a sternal lesion and several lung nodules with high somatostatin receptor density. Also, on the next day, FDG PET/CT was performed, which confirmed the findings. Considering the high levels of somatostatin receptor expression in such metastases, we planned lu177 DOTA-TATE therapy. After two cycles of lu177 DOTA-TATE injection, serum thyroglobulin significantly dropped, and she claimed that her sternal pain and dyspnea were much better. This was the case of a patient suffering from iodine-refractory follicular thyroid carcinoma, with somatostatin-receptor expression, treated with 177Lu-DOTA-TATE, showing a significant response. Sociedade Brasileira de Endocrinologia e Metabologia 2022-03-23 /pmc/articles/PMC9832896/ /pubmed/35315988 http://dx.doi.org/10.20945/2359-3997000000451 Text en https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Ataei-Nakhaei, Saeideh Aryana, Kamran Mostafavi, Sayyed Mostafa Kosari, Hadis Mohammadzadeh Esmatinia, Mohammad Aghaee, Atena Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment |
title | Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment |
title_full | Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment |
title_fullStr | Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment |
title_full_unstemmed | Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment |
title_short | Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment |
title_sort | peptide receptor radionuclide therapy (prrt) in radioiodine-refractory thyroid cancer: a case report of significant response to lu177 dota-tate treatment |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832896/ https://www.ncbi.nlm.nih.gov/pubmed/35315988 http://dx.doi.org/10.20945/2359-3997000000451 |
work_keys_str_mv | AT ataeinakhaeisaeideh peptidereceptorradionuclidetherapyprrtinradioiodinerefractorythyroidcanceracasereportofsignificantresponsetolu177dotatatetreatment AT aryanakamran peptidereceptorradionuclidetherapyprrtinradioiodinerefractorythyroidcanceracasereportofsignificantresponsetolu177dotatatetreatment AT mostafavisayyedmostafa peptidereceptorradionuclidetherapyprrtinradioiodinerefractorythyroidcanceracasereportofsignificantresponsetolu177dotatatetreatment AT kosarihadismohammadzadeh peptidereceptorradionuclidetherapyprrtinradioiodinerefractorythyroidcanceracasereportofsignificantresponsetolu177dotatatetreatment AT esmatiniamohammad peptidereceptorradionuclidetherapyprrtinradioiodinerefractorythyroidcanceracasereportofsignificantresponsetolu177dotatatetreatment AT aghaeeatena peptidereceptorradionuclidetherapyprrtinradioiodinerefractorythyroidcanceracasereportofsignificantresponsetolu177dotatatetreatment |